• 5 min read
• Published on 26 September 2025
Listen to article
5:50Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
A Dose of Reality for Pharma Investors
Well, it finally happened. The Americans have built a wall, not of bricks and mortar, but of tariffs. And this one is aimed squarely at the global pharmaceutical industry. A whopping 100% tariff on drugs from any company without a significant manufacturing presence in the United States isn't just a policy shift, it's a declaration of economic war. For investors who have grown accustomed to the cosy, globalised world of drug production, it’s time to wake up and smell the over-brewed coffee.
Let’s not mince words. This tariff is a sledgehammer designed to reshape an entire industry. The logic is brutally simple. If an imported pill suddenly costs twice as much as its American-made equivalent, which one do you think hospitals and patients will choose? It’s not about patriotism, it’s about pounds and pence, or in this case, dollars and cents.
For years, I’ve watched big pharma companies chase cheaper labour costs around the globe, turning their supply chains into a tangled mess of international dependencies. Now, the chickens are coming home to roost. Suddenly, companies like Pfizer, Bristol-Myers Squibb, and Eli Lilly, with their expensive American factories, don't look like dinosaurs. They look like geniuses. Their domestic infrastructure has transformed from a costly burden into a formidable competitive moat, practically overnight.
The obvious winners are, of course, the big pharmaceutical giants who kept their production lines humming on home soil. They now find themselves in a protected playground, shielded from foreign competition. But to me, the story is far more interesting when you look beyond the household names. This policy creates a ripple effect that could be far more lucrative for the discerning investor.
Think about it. When a factory is built, it’s not just the factory owner who profits. It’s the electricians, the plumbers, and the suppliers of raw materials. The same principle applies here. As domestic drug production ramps up, a whole ecosystem of supporting businesses stands to benefit. Contract research organisations that conduct clinical trials, specialist packaging firms, and quality control labs will all see a surge in demand. To me, this isn't just about picking one or two stocks. It's about understanding a whole new ecosystem. The theme of Domestic Pharma Tariffs: What's Next for Investors is far more complex than simply backing the big names.
Of course, no opportunity comes without a healthy dose of risk. And I’d be remiss not to pour a little cold water on the excitement. For one, political winds can change. What one administration builds with tariffs, the next could dismantle with a trade agreement. Relying on government protection is like building your house on sand, it’s comfortable until the tide comes in.
Furthermore, let’s not forget why these companies moved production overseas in the first place. It’s expensive to make things in America. While the tariffs provide a buffer, they don’t magically erase higher labour costs and stricter regulations. Companies might find their profit margins squeezed even as their revenues climb. There’s also the simple matter of time. You can’t build a state-of-the-art pharmaceutical plant in a weekend. The transition period could be messy, with potential supply disruptions and market volatility. This is a long game, not a get-rich-quick scheme.
View the full Basket:Domestic Pharma Tariffs: What's Next for Investors
View the full Basket:Domestic Pharma Tariffs: What's Next for Investors
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article